Physician profile
William C Willmott
NPI 1447286455
$8,602.12
in general payments reported to CMS, 2019-2025
49 companies · $1,682 in 2025
The $1,682 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,173 · 2020: $760 · 2021: $693 · 2022: $1,183 · 2023: $1,379 · 2024: $1,732 · 2025: $1,682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,703 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,703.38 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,867.73 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Inspire Medical Systems, INC. | $715.34 | 2022-2025 | Inspire |
| Astrazeneca Pharmaceuticals Lp | $591.57 | 2019-2025 | Breztri, Tezspire, Fasenra |
| Actelion Pharmaceuticals US, INC. | $499.52 | 2019-2025 | Opsumit, Uptravi |
| Grifols USA, LLC | $406.59 | 2019-2025 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $404.25 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Insmed, INC. | $378.46 | 2019-2025 | Arikayce, Brinsupri |
| Takeda Pharmaceuticals U.S.A., INC. | $378.32 | 2020-2025 | Glassia |
| Harmony Biosciences LLC | $363.95 | 2020-2024 | Wakix |
| Genzyme Corporation | $302.98 | 2020-2025 | |
| Mylan Specialty L.P. | $301.74 | 2019-2024 | Yupelri |
| Jazz Pharmaceuticals INC. | $245.78 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $235.33 | 2019-2025 | Dupixent |
| Sunovion Pharmaceuticals INC. | $194.67 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $189.65 | 2019-2025 | Winrevair |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Willmott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.